Comparing pulsed field ablation and thermal energy catheter ablation for paroxysmal atrial fibrillation: a cost-effectiveness analysis of the ADVENT trial
PFA was at least as cost-effective as conventional thermal ablation modalities for treatment of paroxysmal AF and potentially reduces US healthcare payer costs. Providers and payers should consider designating PFA among the preferred first-line therapies for eligible patients.
Authors
- Benjamin G. Cohen
- MOUSSA C. MANSOUR (ORCID: https://orcid.org/0000-0003-3326-9973)
- Vivek Y. Reddy (ORCID: https://orcid.org/0000-0002-5638-4993)
- Edward P. Gerstenfeld (ORCID: https://orcid.org/0000-0002-7200-3521)
- William V. Padula (ORCID: https://orcid.org/0000-0003-1161-6954)
- Brad Sutton
- Caroline M. Jacobsen
- Alexandra Paffrath
- Rachel Nadboy
Institutions
- University of Southern California (US)
- University of California, San Francisco (US)
- Njala University (SL)
- Boston Scientific (United States) (US)
- Massachusetts General Hospital (US)
- Mount Sinai Hospital (US)
- Boston Scientific (Netherlands) (NL)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1080/13696998.2024.2441071
- Citations
- 9
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.62